摘要
目的观察多巴胺受体激动剂普拉克索对早期帕金森(PD)病人的治疗效果。方法选择早期PD病人60例,随机分成美多芭组和普拉克索组,两组病人从小剂量开始渐增加剂量至症状稳定后维持治疗,采用改良WEBSTER和帕金森统一量表(UPDRS)评分比较两组治疗1、3个月后的效果。结果普拉克索组治疗1月时改良的WEBSTER评分和UPDRS评分较治疗前无显著改善(P>0.05),改良WEBSTER评分3个月时较治疗前及1月时有显著改善(F=35.286,q=11.92、7.69,P<0.01);UPDRS评分3个月时较治疗前及1月时有显著改善(F=8.812,q=5.88、3.68,P<0.01)。美多芭组WEBSTER评分于治疗1、3个月后较治疗前均有显著改善(F=76.619,q=11.85、17.31,P<0.01);UPDRS评分于治疗1、3个月后较治疗前均有显著改善(F=39.032,q=9.34、11.85,P<0.01);WEBSTER评分和UPDRS评分治疗3个月时较治疗1月时无进一步改善(P>0.05)。美多芭组于治疗1、3个月时UPDRS评分改善均优于普拉克索组(t=3.767、3.347,P<0.01、0.05)。结论普拉克索能改善早期帕金森病人的临床症状,但普拉克索短期内在控制临床症状方面效果不及美多芭。
Objective To investigate the therapeutic efficacy of Pramipexole for early Parkinson disease（PD）. Methods Sixty patients with PD in their early stage were enrolled and divided into Madopar and Pramipexole group in random.The drugs were started from low dose,and gradually increased until the symptoms were stable and then maintenance therapy was keeping for 1-3 months.WEBSTER score and unified Parkinson disease rating scale（UPDRS） were used to assess the efficacy. Results As compared with pre-treatment,both WEBSTER score and UPDRS score after one month of treatment with Pramipexole was not significantly different（P0.05）;after three months of treatment,WEBSTER score showed markedly improved compared with pretherapy and after one month of therapy（F=35.286,q=11.92,P0.01）;the same result was obtained by UPDRS（q=7.69,P0.01）.In Madopar group,WEBSTER score showed that after one-and three-month Madopar therapy,the patients＇ condition was much improved than pretherapy（F=76.619;q=11.85,17.31;P0.01）;UPDRS score showed a similar result（F=39.032;q=9.34,11.85;P0.01）.As for WEBSTER and UPDRS score,the result showed no further improvement was achieved after three months of therapy as compared with after one-month medication（P0.05）.After one and three months of therapy,the UPDRS score indicated that the improvement of Madopar group was better than Pramipexole（t=3.767,3.347;P0.01,0.05）. Conclusion Pramipexole is effective for improving the symptoms of patients with early Parkinson disease,but in controlling the clinical signs in short duration,Pramipexole is not as good as Madopar.
出处
《青岛大学医学院学报》
CAS
2010年第3期263-265,共3页
Acta Academiae Medicinae Qingdao Universitatis
关键词
帕金森病
普拉克索
美多芭
治疗结果
parkinson disease
madopar
pramipexole
treatment outcome
